

Market Applicability														
Market	DC	FL & FHK	FL MMA	FL LTC	GA	KS	KY	MD	NJ	NV	NY	TN	TX	WA
Applicable	X	X	NA	NA	X	NA	X	X	X	X	X	NA	NA	X

\*FHK- Florida Healthy Kids

## Bosulif (bosutinib)

Override(s)	Approval Duration
Prior Authorization Quantity Limit	1 year

Medications	Quantity Limit
Bosulif (bosutinib)	May be subject to quantity limit

### APPROVAL CRITERIA

Requests for Bosulif (bosutinib) may be approved if the following criteria are met:

- I. Individual has a diagnosis of Chronic myelogenous leukemia (CML); **AND**
  - A. Individual has newly-diagnosed chronic phase Philadelphia-positive (Ph+) or BCR-ABL1 positive (test results confirmed) disease; **OR**
  - B. Individual has chronic, accelerated, or blast phase Ph+ disease, with resistance or intolerance to prior treatment; **OR**
  - C. Individual is using for post-allogeneic hematopoietic stem cell transplant (HCT) follow-up treatment (NCCN2A); **OR**
  - D. Individual is using as primary treatment in accelerated phase disease as monotherapy (NCCN 2A) ; **OR**
  - E. Individual is using in combination as primary treatment in lymphoid blast phase or myeloid blast phase disease; **OR**
  - F. Individual is using in post-allogeneic HCT therapy for those with prior accelerated or blast phase disease with complete cytogenetic response; **OR**
  - G. Individual has any of the following documented mutations (test result confirmed):
    1. E255K/V; **OR**

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.

Market Applicability														
Market	DC	FL & FHK	FL MMA	FL LTC	GA	KS	KY	MD	NJ	NV	NY	TN	TX	WA
Applicable	X	X	NA	NA	X	NA	X	X	X	X	X	NA	NA	X

\*FHK- Florida Healthy Kids

2. F317L/V//C; **OR**
3. F359V/C/I; **OR**
4. T315A; **OR**
5. Y253H

**OR**

II. Individual has a diagnosis of relapsed/refractory Ph+ Acute Lymphoblastic Leukemia (ALL) (NCCN 2A).

State Specific Mandates		
State name	Date effective	Mandate details (including specific bill if applicable)
N/A	N/A	N/A

**Key References:**

1. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.: 2018. URL: <http://www.clinicalpharmacology.com>. Updated periodically.
  2. DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>. Accessed: October 2018.
  3. DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.
  4. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2018; Updated periodically.
  5. The NCCN Drugs & Biologics Compendium (NCCN Compendium™) © 2018 National Comprehensive Cancer Network, Inc. Available at: NCCN.org. Updated periodically.
- The NCCN Drugs & Biologics Compendium (NCCN Compendium™) © 2018 National Comprehensive Cancer Network, Inc. Available at: NCCN.org. Updated periodically.

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.